{"id":{"repo_id":"usf","oai_identifier":"oai:digitalcommons.usf.edu:etd-10446"},"canonical_url":"https://search.ndltd.org/etd/usf/oai:digitalcommons.usf.edu:etd-10446","repository":{"repo_id":"usf","name":"University of South Florida","base_url":"https://digitalcommons.usf.edu/do/oai/"},"display":{"title":"Evolution of Targeted Therapy Resistance in EML4-ALK Positive Non-Small Cell Lung Cancer","abstract":"Targeted therapies have emerged as potent treatments that lead to the remission of many tumors. However, they rarely cure cancers in advanced, metastatic settings. This is due to the evolution of resistance, which in turn can be ascribed to the survival of small subpopulations of tolerant and/or resistant cells. Here we investigated the evolution of resistance to EML4-ALK inhibitors in non-small cell lung cancer (NSCLC) and demonstrated that resistance evolves gradually, from unique pre-treatment sub-populations, as multiple resistance mechanisms accumulate in a Darwinian fashion. Despite accumulating multiple changes, cells evolved, in parallel, toward similar inhibitor specific phenotypes. Evolving cells have unique vulnerabilities that can be targeted with collateral sensitivity agents before full resistance evolves. These conclusions, obtained from in vitro studies, are applicable to the evolution of resistance in vivo. However, the evolution of resistance in vivo is also strongly influenced by microenvironmental therapy resistance. These findings could allow physicians to base treatment strategies on the future evolutionary trajectories of tumors and exploit unique vulnerabilities not just after, but during, the evolution of resistance.","abstract_html":"Targeted therapies have emerged as potent treatments that lead to the remission of many tumors. However, they rarely cure cancers in advanced, metastatic settings. This is due to the evolution of resistance, which in turn can be ascribed to the survival of small subpopulations of tolerant and/or resistant cells. Here we investigated the evolution of resistance to EML4-ALK inhibitors in non-small cell lung cancer (NSCLC) and demonstrated that resistance evolves gradually, from unique pre-treatment sub-populations, as multiple resistance mechanisms accumulate in a Darwinian fashion. Despite accumulating multiple changes, cells evolved, in parallel, toward similar inhibitor specific phenotypes. Evolving cells have unique vulnerabilities that can be targeted with collateral sensitivity agents before full resistance evolves. These conclusions, obtained from in vitro studies, are applicable to the evolution of resistance in vivo. However, the evolution of resistance in vivo is also strongly influenced by microenvironmental therapy resistance. These findings could allow physicians to base treatment strategies on the future evolutionary trajectories of tumors and exploit unique vulnerabilities not just after, but during, the evolution of resistance.","abstract_has_math":false,"creators":["Vander Velde, Robert"],"institution":"University of South Florida","degree_name":"Doctor of Philosophy (Ph.D.)","degree_level":"Dissertation","degree_discipline":"Biology (Integrative Biology)","degree_department":null,"school":null,"contributors":["Andriy Marusyk, Ph.D.","Subhra Mohapatra, Ph.D.","Robert Deschenes, Ph.D.","George Blanck, Ph.D.","David Basanta, Ph.D.","Sydney Shaffer, M.D., Ph.D."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2021,"date_issued":"2021-06-30T07:00:00Z","date_published":"2021-06-30T07:00:00Z","updated_at":"2026-11-19T08:47:41Z","subjects":["Cancer","EML4-ALK","Evolution","Non-Small Cell Lung Cancer","Resistance","Biology","Molecular Biology","Oncology"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.usf.edu/etd/9249","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://digitalcommons.usf.edu/etd/9249","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://digitalcommons.usf.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Adigitalcommons.usf.edu%3Aetd-10446","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Andriy Marusyk, Ph.D.","Subhra Mohapatra, Ph.D.","Robert Deschenes, Ph.D.","George Blanck, Ph.D.","David Basanta, Ph.D.","Sydney Shaffer, M.D., Ph.D."]},{"key":"dc:creator","label":"Author","values":["Vander Velde, Robert"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2021-06-30T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Biology (Integrative Biology)"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation","Ph.D."]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy (Ph.D.)"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of South Florida"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Cancer","EML4-ALK","Evolution","Non-Small Cell Lung Cancer","Resistance","Biology","Molecular Biology","Oncology"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.usf.edu/etd/9249"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Targeted therapies have emerged as potent treatments that lead to the remission of many tumors. However, they rarely cure cancers in advanced, metastatic settings. This is due to the evolution of resistance, which in turn can be ascribed to the survival of small subpopulations of tolerant and/or resistant cells. Here we investigated the evolution of resistance to EML4-ALK inhibitors in non-small cell lung cancer (NSCLC) and demonstrated that resistance evolves gradually, from unique pre-treatment sub-populations, as multiple resistance mechanisms accumulate in a Darwinian fashion. Despite accumulating multiple changes, cells evolved, in parallel, toward similar inhibitor specific phenotypes. Evolving cells have unique vulnerabilities that can be targeted with collateral sensitivity agents before full resistance evolves. These conclusions, obtained from in vitro studies, are applicable to the evolution of resistance in vivo. However, the evolution of resistance in vivo is also strongly influenced by microenvironmental therapy resistance. These findings could allow physicians to base treatment strategies on the future evolutionary trajectories of tumors and exploit unique vulnerabilities not just after, but during, the evolution of resistance."]},{"key":"dc:title","label":"Title","values":["Evolution of Targeted Therapy Resistance in EML4-ALK Positive Non-Small Cell Lung Cancer"]}]}],"canonical_facts":{"dc:contributor":["Andriy Marusyk, Ph.D.","Subhra Mohapatra, Ph.D.","Robert Deschenes, Ph.D.","George Blanck, Ph.D.","David Basanta, Ph.D.","Sydney Shaffer, M.D., Ph.D."],"dc:creator":["Vander Velde, Robert"],"dc:date":["2021-06-30T07:00:00Z"],"dc:description":["Targeted therapies have emerged as potent treatments that lead to the remission of many tumors. However, they rarely cure cancers in advanced, metastatic settings. This is due to the evolution of resistance, which in turn can be ascribed to the survival of small subpopulations of tolerant and/or resistant cells. Here we investigated the evolution of resistance to EML4-ALK inhibitors in non-small cell lung cancer (NSCLC) and demonstrated that resistance evolves gradually, from unique pre-treatment sub-populations, as multiple resistance mechanisms accumulate in a Darwinian fashion. Despite accumulating multiple changes, cells evolved, in parallel, toward similar inhibitor specific phenotypes. Evolving cells have unique vulnerabilities that can be targeted with collateral sensitivity agents before full resistance evolves. These conclusions, obtained from in vitro studies, are applicable to the evolution of resistance in vivo. However, the evolution of resistance in vivo is also strongly influenced by microenvironmental therapy resistance. These findings could allow physicians to base treatment strategies on the future evolutionary trajectories of tumors and exploit unique vulnerabilities not just after, but during, the evolution of resistance."],"dc:identifier":["https://digitalcommons.usf.edu/etd/9249"],"dc:subject":["Cancer","EML4-ALK","Evolution","Non-Small Cell Lung Cancer","Resistance","Biology","Molecular Biology","Oncology"],"dc:title":["Evolution of Targeted Therapy Resistance in EML4-ALK Positive Non-Small Cell Lung Cancer"],"thesis:degree_discipline":["Biology (Integrative Biology)"],"thesis:degree_level":["Dissertation","Ph.D."],"thesis:degree_name":["Doctor of Philosophy (Ph.D.)"],"thesis:institution_name":["University of South Florida"]},"updated_at":"2026-11-19T08:47:41Z"}